U.K. Inflation Cooled in March as Bank of England Prepares Rate Cuts
By Ed Frankl
The U.K.'s annual rate of inflation cooled to a two-and-a-half year low in March despite being a touch hotter than expected, though not likely enough to derail the Bank of England from lowering its key interest rate later this year.
Consumer prices were 3.2% higher in March than the same month a year earlier, cooling from the 3.4% annual rate of inflation recorded in February, the Office for National Statistics said Wednesday. The reading, the lowest since September 2021, was marginally higher than the 3.1% expected by a consensus of economists polled by The Wall Street Journal.
Offering further reassurance to policymakers at the BOE, core inflation, which strips out volatile energy and food prices, also slowed to 4.2%, from 4.5% in February.
The BOE left its key rate unchanged at a 16-year high in March, but signaled that it is likely to cut later this year, while giving little guidance on the exact timing.
Write to Ed Frankl at edward.frankl@wsj.com
(END) Dow Jones Newswires
April 17, 2024 02:23 ET (06:23 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track